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Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and
effect of analytical performances on fentanyl parameter estimation
Abstract
This study describes the pharmacokinetics of intravenously administered (i.v.) fentanyl citrate, and its primary
metabolite norfentanyl in Holstein calves. Eight calves (58.6 ± 2.2 kg), aged 3–4 weeks, were administered
fentanyl citrate at a single dose of 5.0 μg/kg i.v. Blood samples were collected from 0 to 24 hr. Plasma
(nor)fentanyl concentrations were determined using liquid chromatography with mass spectrometry and a
lower limit of quantification (LLOQ) of 0.03 ng/ml. To explore the effect of analytical performance on
fentanyl parameter estimation, the noncompartmental pharmacokinetic analysis was then repeated with a
hypothetical LLOQ value of 0.05 ng/ml. Terminal elimination half‐life was estimated at 12.7 and 3.6 hr for
fentanyl and norfentanyl, respectively. For fentanyl, systemic clearance was estimated at 2.0 L hr−1 kg−1,
volume of distribution at steady‐state was 24.8 L/kg and extraction ratio was 0.42. At a hypothetical LLOQ of
0.05 ng/ml fentanyl half‐life, volume of distribution at steady‐state and clearance were, respectively, of 3.0 hr,
8.8 L/kg and 3.4 L kg−1 hr−1. Fentanyl citrate administered i.v. at 5.0 μg/kg can reach levels associated with
analgesia in other species. Pharmacokinetic parameters should be interpreted with respect to LLOQ, as lower
limits can influence estimated parameters, such as elimination half‐life or systemic clearance and have
significant impact on dosage regimen selection in clinical practice.
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Abstract 
This study describes the pharmacokinetics of intravenously administered (IV) fentanyl 
citrate, and its primary metabolite norfentanyl in Holstein calves.  
 
Eight calves (58.6 +/- 2.2 kg), aged 3-4 weeks, were administered fentanyl citrate at a 
single dose of 5.0 µg/kg IV. Blood samples were collected from 0 to 24 hours. Plasma 
(nor)fentanyl concentrations were determined using liquid chromatography with mass 
spectrometry and a lower limit of quantification (LLOQ) of 0.03 ng/mL. The 
noncompartmental pharmacokinetic analysis was then repeated with a hypothetical 
LLOQ value of 0.05 ng/mL.  
 
Terminal elimination half-life was estimated at 12.7 and 3.6 hours for fentanyl and 
norfentanyl, respectively. For fentanyl, systemic clearance was estimated at 2.0 L/hr/kg, 
volume of distribution at steady state was 24.8 L/kg, and extraction ratio was 0.42. At a 
hypothetical LLOQ of 0.05 ng/mL fentanyl half-life, volume of distribution at steady 
state, and clearance were respectively of 3.0 hr, 8.8 L/kg, and 3.4 L/kg/hr. 
 
Fentanyl citrate administered IV at 5.0 µg/kg can reach levels associated with analgesia 
in other species. Pharmacokinetic parameters should be interpreted with respect to 
LLOQ, as lower limits can influence estimated parameters, such as elimination half-life 
or systemic clearance and have significant impact on dosing regimen selection in 
clinical practice.  
 
Key words. 
Fentanyl, Cattle, Calves, Norfentanyl  
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Introduction 1 
Analgesia for cattle during production, surgical, and medical procedures is an important 2 
tool for promoting animal welfare. While cattle are commonly subjected to potentially 3 
painful production procedures and non-routine surgical procedures, practitioners have 4 
limited options in terms of pain management as in the US there are currently no drugs 5 
labelled for analgesia in cattle.  6 
The synthetic mu receptor opioid agonist fentanyl is commonly used to provide 7 
analgesia in veterinary species. Morphine and butorphanol are opioid analgesics that 8 
currently are currently used as an intravenous (IV) bolus in cattle. Morphine, is a 9 
primary mu opioid agonist that is used for the treatment of pain in a wide variety of 10 
veterinary species. Butorphanol has also been described for use in many veterinary 11 
species and is a partial opioid agonist with activity as an agonist for the kappa receptor 12 
and weak mu receptor antagonist activity. Butorphanol is thought to have an analgesic 13 
value of approximately four to seven times that of morphine.  14 
With a potency that is approximately 100 times more than morphine, and a rapid onset, 15 
fentanyl is an ideal clinical analgesic in veterinary medicine. Fentanyl is primarily 16 
metabolized by cytochrome P450 3A enzymes to norfentanyl(Clavijo, Thomas et al., 17 
2011). There are several additional minor pathways it the metabolism of fentanyl, 18 
primarily amide hydrolysis to despropionyl fentanyl as well as alkyl hydroxylation to 19 
hydroxyfentanyl.  20 
Among large animal species, the pharmacokinetics (PK) of IV fentanyl has been 21 
described in sheep(Ahern, Soma et al., 2010), goats(Carroll, Hooper et al., 1999), 22 
alpacas(Lovasz, Aarnes et al., 2017), and horses(Maxwell, Thomasy et al., 2003). In 23 
small animals, the IV pharmacokinetics of fentanyl has also been described. Adverse 24 
reactions to fentanyl include an increase in locomotor activity in horses (Kamerling, 25 
DeQuick et al., 1985), and respiratory depression when too high systemic 26 
concentrations are reached (30 ng/mL) in dogs (Arndt, Mikat et al., 1984). 27 
Pharmacokinetics of fentanyl metabolites, while readily available in human medical 28 
studies, are limited in veterinary medicine. Currently limited to studies reporting 29 
norfentanyl concentrations in chickens(Delaski, Gehring et al., 2017), and 30 
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primates(Koch, Isaza et al., 2004), as well as not detecting measurable quantities of 31 
norfentanyl in dogs(Lin, Wang et al., 1981).  32 
While practitioners routinely utilize analgesic drugs in a legal extra-label manner, there 33 
are few reports of the pharmacokinetics of fentanyl in ruminant species, and no reports 34 
of the use of this analgesic therapy in cattle. Due to the increased analgesic activity of 35 
fentanyl compared to morphine and butorphanol it may have clinical uses for bovine 36 
analgesia during surgical procedures. 37 
The aim of this study was to describe the pharmacokinetics of fentanyl citrate and its 38 
primary metabolite norfentanyl when administered as an IV bolus in calves, as well as to 39 
report any adverse reactions. A secondary goal of this study was to examine the impact 40 
of the bioanalytical quantification limit of fentanyl with respect to pharmacokinetic 41 
parameter estimation.  42 
  43 
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Materials and Methods 44 
Experimental Animals 45 
This study was completed at the Iowa State University Dairy Farm. Eight female 46 
Holstein calves were enrolled in the study. The age of these calves ranged from 23 to 47 
30 days, weighed 58.6 +/- 2.2 kg, and were procured from a single source farm. 48 
Approval for the study was secured from the Institution Animal Care and Use 49 
Committee (Log # 7-16-8318-B) at Iowa State University. The calves were housed in 50 
individual pens since birth, and the study took place in the same individual pens for 51 
each calf. The calves were housed in a climate-controlled calf raising facility, and no 52 
alterations to feeding or handling schedule was made for this study. During the pre-53 
study time period, all calves were trained to be restrained by a hand placed under the 54 
mandible and behind the poll. Criteria for enrollment in this study included a physical 55 
assessment by a veterinarian that yielded vital signs within the normal limits for a bovine 56 
calf, no previous history of medical illness as well as no history of a previously 57 
administered medication. Prior to and during the study all calves were fed a diet that 58 
wither met or exceeded the NRC requirements for maintenance and growth of bovine 59 
calves. 60 
Twenty hours prior to initiation of the study the calves were restrained and 2 IV jugular 61 
catheters were aseptically placed. The skin was aseptically prepared utilizing 4 62 
alternating scrubs of chlorhexidine surgical scrub and 70% isopropyl alcohol. Prior to 63 
catheter placement the skin at the catheter site was infiltrated with 2% lidocaine. The 64 
calf was restrained by study personnel and a 14-gauge catheter was placed in each 65 
jugular vein. An injection port was placed and the catheters were sutured to the skin and 66 
wrapped for security. 67 
 68 
Experimental Design and Sample Collection 69 
Calves were administered a single 5.0 µg/kg IV bolus of fentanyl citrate (Fentanyl 70 
Citrate, Hospira Inc, Lake Forrest, Il) via a catheter inserted in the left jugular vein. 71 
Blood collection was achieved through a catheter in the right jugular vein at 2, 5, 10, 30, 72 
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45, and 60 minutes, and 1.5, 2, 2.5, 3, 4, 6, 10, 16, and 24 hours after administration. 73 
Starting at the 2-hour sampling time point, heart and respiratory rates were measured at 74 
each sampling timepoint up to 24 hours. 75 
At each sampling timepoint blood was collected from the catheter using a 12-mL syringe 76 
and placed into sodium heparin tubes (BD Vacutainer, Franklin Lakes, NJ). The 77 
samples were then centrifuged at 1500 G for 10 minutes. The plasma was pipetted off 78 
and transferred to cryovials which were then stored at -80 C until analysis. 79 
 80 
Sample Analysis 81 
Plasma concentrations of fentanyl, and its metabolite norfentanyl were determined by 82 
liquid chromatography-mass spectrometry (LC-MS) after precipitation of proteins by 83 
acetonitrile. Briefly, plasma samples were thawed and vortexed, and 200uL aliquots 84 
were transferred into a vial with 800uL of internal standard, fentanyl-D5, in acetonitrile 85 
with 0.1% formic acid added. Samples were vortexed and then centrifuged at 7500 rpm 86 
for 20 minutes. The supernatant was then transferred and the samples were dried 87 
down, then reconstituted in 125uL of 25% acetonitrile in water, vortexed and transferred 88 
into an autosampler vial (with glass insert) and then centrifuged for 20 minutes at 2400 89 
rpm and analyzed via LC-MS/MS. The LC-MS system consisted of an Agilent 1100 90 
HPLC (Agilent Technologies, Santa Clara, CA, USA) coupled to a Thermo LTQ ion trap 91 
mass spectrometer (Thermo Scientific, San Jose, CA, USA). The lower limit of 92 
quantification (LLOQ) for fentanyl and its metabolite was 0.03 ng/mL for this assay. 93 
 94 
Pharmacokinetic Analysis 95 
Pharmacokinetic analysis of total fentanyl and norfentanyl plasma concentrations was 96 
completed using a statistical moment (i.e. non-compartmental) approach in commercial 97 
software (Phoenix WinNonlin 7.0, Certara, Princeton, NJ, USA). Time versus 98 
concentration figures for fentanyl and norfentanyl were produced via a commercial 99 
program (GraphPad Prism 7, GraphPad Software, Inc, La Jolla, CA, USA). 100 
Standard PK parameters were generated for individual calves, as follows: 101 
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o Maximum (nor)fentanyl concentration, C0 (fentanyl) or Cmax (norfentanyl); 102 
o Time of maximum norfentanyl concentration, Tmax; 103 
o Area under (nor)fentanyl concentration-time curve, AUClast and AUCinf; 104 
o Area under the moment curve, AUMCinf; 105 
o (Nor)fentanyl mean residence time,  106 
MRT = AUMCinf  ⁄ AUC inf; 107 
o Slope of the elimination phase λz, computed by linear regression of the 108 
logarithmic concentration vs. time curve during the elimination phase; 109 
o (Nor)fentanyl terminal half-life,  110 
T1/2 (λz) = ln (2) ⁄ λz; 111 
o Fentanyl systemic clearance, CL = Dose ⁄ AUC inf; 112 
o Volume of distribution of fentanyl during the elimination phase,  113 
Varea = Dose ⁄ (AUCinf x λz); 114 
o Volume of distribution of fentanyl at steady-state, Vss = CL x MRT  115 
 116 
For data analysis, the first value below the LLOQ was inferred to be LLOQ/2, and 117 
subsequent data points were excluded from the analysis. A linear/log trapezoidal rule 118 
was used to estimate the area under the (nor)fentanyl time-curves. Summary statistics 119 
on the individual PK parameters were performed thereafter to derive the geometric 120 
mean, median and (min-max) range. 121 
 122 
For fentanyl, the extraction ratio (Ebody) was calculated as reported by Toutain et 123 
al(Toutain & Bousquet-Melou, 2004), with: 124 
EBody = Systemic clearance / Cardiac output     [Equation 1] 125 
First calculated for each individual calf, and then combined for a mean value. With the 126 
calf cardiac output calculated as follows:  127 
Cardiac output = 180 x BW(kg)-0.19      [Equation 2] 128 
 129 
In a second step and using the same raw source data, an hypothetical analytical LLOQ 130 
of 0.05 ng/mL, as reported in the literature in other species(Lovasz, Aarnes et al., 2017), 131 
was applied and the pharmacokinetic analysis for fentanyl only was repeated using the 132 
same workflow as described above. 133 
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Results 135 
Animal Health 136 
At enrollment, all study subjects were assessed to be healthy and to have parameters 137 
within the normal limits for calves of their respective ages. The injections were well 138 
tolerated by all calves, with no adverse effects noted throughout the entire study period. 139 
For heart rate, respiratory rate, and temperature no significant elevation or depression 140 
from baseline was reported, with the exception of excitement at the timepoints that 141 
coincided with the feeding of the calves. Follow up examination 2 weeks and 2 months 142 
after the study revealed no abnormalities in behavior or physical assessment. 143 
 144 
Pharmacokinetics of fentanyl and its metabolites using a LLOQ of 0.03 ng/mL 145 
No calf had detectable fentanyl or metabolites in plasma at time zero. The individual 146 
time-course of fentanyl and norfentanyl total concentrations in plasma can be found in 147 
Figures 1 and 2, respectively. Geometric mean and standard deviations disposition 148 
profiles are presented in Figures 3 and 4 for fentanyl and norfentanyl, respectively. 149 
Among individuals there appears to be limited variation of time versus concentration 150 
data for fentanyl as opposed to norfentanyl. For the LLOQ of 0.03 ng/mL 4.2% (5/120) 151 
of the post administration data points had values below the LLOQ. For the theoretical 152 
LLOQ of 0.05 ng/mL 21.7% (26/120) of the post administration data points had values 153 
below the LLOQ. 154 
Table 1 summarizes the pharmacokinetic parameters for fentanyl and norfentanyl when 155 
administered IV. For fentanyl, the systemic clearance was almost 2 L/kg/hr. The 156 
average extraction ratio was calculated to be 0.41 ± 0.10. The AUC% extrapolation was 157 
estimated to be inferior to 20% (15.4%), while the steady-state volume of distribution 158 
(Vss) was 24.8 L/kg. The elimination half-life T1/2 (λz) was estimated at approximately 159 
12 hours.  160 
For norfentanyl the AUC% extrapolation was estimated to be inferior to 20% (7.2%). 161 
CMAX and TMAX of norfentanyl were 0.3 ng/mL, and 1.1 hr respectively. The elimination 162 
half-life T1/2 λz was estimated at 12.7 hours. 163 
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 164 
 165 
 166 
Pharmacokinetics of fentanyl and its metabolites using a LLOQ of 0.05 ng/mL 167 
A comparison of the fentanyl estimated PK parameters with a LLOQ of 0.03 vs. 0.05 168 
ng/mL is provided in Table 2. Despite this relatively small difference in analytical 169 
sensitivity (0.02 ng/mL), a noted lack of agreement among parameters was observed. 170 
Compared to the quantification limit of 0.03 ng/mL, the clearance of fentanyl was 171 
markedly increased (164 % increased) when a hypothetical quantification limit of 0.05 172 
ng/mL was utilized on the study data. In contrast, the estimated volume of distribution 173 
markedly decreased (by 68%), and the elimination half-life was 12 hr shorter as 174 
compared with the 0.03 ng/mL LLOQ threshold. Interestingly, with the higher 175 
quantification limit, the estimated elimination half-life was closer in value to what is 176 
reported in the literature for other ruminant species, with a LLOQ ranging from 0.01 177 
(sheep) to 0.1 (goat) ng/mL (Table 3).  178 
  179 
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Discussion 180 
To the best of our knowledge, this is the first report of the pharmacokinetics of fentanyl 181 
in calves. Although the cohort sampling could potentially be a source of bias for this 182 
study, it was thought to be minimal as calves had acclimated to the individual pens prior 183 
to the study, and the group of individual pens used for the study was from the same 184 
block of eight stalls in the temperature, humidity, and ventilation controlled barn. The 185 
age and size of the calves utilized for this study was designed to mimic the age of 186 
calves presented to the author’s hospital for surgical procedures that could potentially 187 
benefit from fentanyl analgesia. 188 
In the United States, there is currently no approved formulation of fentanyl citrate for 189 
cattle. However, in practice calves routinely undergo orthopedic and other surgical 190 
procedures that warrant post-operative analgesia. Several concentrations of fentanyl 191 
have been associated with analgesia in various veterinary species. Plasma fentanyl 192 
values of 1.07, 0.95, and 0.6 ng/mL or greater have been associated with analgesia in 193 
cats(Robertson, Taylor et al., 2005), dogs(Robinson, Kruse-Elliott et al., 1999) and 194 
people(Peng & Sandler, 1999), respectively. In humans, few reports suggest that values 195 
as low as 0.2 ng/mL may provide analgesia for individuals that are “opioid naïve” and 196 
have not been previously treated with any drugs in the class(Peng & Sandler, 1999). 197 
The maximum concentration reported in this study (1.5 ng/mL), would be above what is 198 
reported to be an analgesic concentration is other veterinary species, although currently 199 
the threshold required for analgesia in calves is unknown. 200 
Other studies have evaluated the pharmacokinetics of intravenously fentanyl in 201 
horses(Maxwell, Thomasy et al., 2003), sheep(Ahern, Soma et al., 2010; Christou, 202 
Oliver et al., 2015), goats(Carroll, Hooper et al., 1999), and alpacas(Lovasz, Aarnes et 203 
al., 2017). The mean maximum concentration of 1.5 ug/L reported in our study was less 204 
than described by earlier reports in other large animal species when normalized with the 205 
input dose (Table 3). The estimated elimination half-life of fentanyl in calves was 206 
apparently longer compared with other large animal species, such as sheep (3.1 hours), 207 
goats (1.2 hours) and alpacas (1.2 hours)(Lovasz, Aarnes et al., 2017). This must be 208 
interpreted with caution however, as these values are compared to mature animals in 209 
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these previous studies, and drug metabolism can be different between young and older 210 
animals of the same species. In lambs aged between 3 and 37 days it has been noted 211 
that clearance and volume of distribution increase with age(Gauntlett, Fisher et al., 212 
1988). Fentanyl is extracted by the liver via the cytochrome P450 system, and initial 213 
activity of this system is low at birth and increases with age(Gauntlett, Fisher et al., 214 
1988). It is uncertain how adult cattle would metabolize this drug, as there would be 215 
potential for variation from calves. 216 
It is noteworthy that when the estimated elimination half-life is considered (with a LLOQ 217 
of 0.05 ng/mL is applied), the value is much lower (3.0 hr vs 14.9 hr), and this lower 218 
value appears to reconcile with other species when a higher quantification limit is 219 
applied in calves. However, the HL in sheep was fairly short (3h) despite a very low 220 
quantification limit (0.01 ng/mL), therefore, between species differences for fentanyl 221 
metabolism are also expected independent of the analytical method. 222 
While the different quantification limits create different pharmacokinetic parameter 223 
values, these differences are not trivial.  224 
For calculating dosing regimens, clearance is the most important pharmacokinetic 225 
parameter(Toutain & Bousquet-Melou, 2004). A lower LLOQ can have multiple effects 226 
of the pharmacokinetic parameters reported, including clearance. By reducing the 227 
number of samples that are below the limit of quantification (BQL), clearance can be 228 
overestimated(Hing, Woolfrey et al., 2001). A higher LLOQ would theoretically result in 229 
more sample values BQL, and therefore result in a higher clearance. This finding is 230 
supported by the higher average clearance reported for the theoretical 0.05 ng/mL 231 
LLOQ for these calves than the average clearance reported for the 0.03 ng/mL LLOQ 232 
(3371 vs 2061 mL/hr/kg). Similarly, elimination half-life, important in predicting time to 233 
steady-state, as well as drug accumulation, would also be affected by a lower LLOQ. 234 
The relationship between elimination half-life and clearance is as follows(Greenblatt, 235 
1985) : 236 
Elimination half-life = (0.693 x Volume of Distribution) / Clearance.  [Equation 3] 237 
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Therefore, increasing clearance would serve to underestimate the elimination half-life. 238 
This is also supported by the theoretical exercise as the elimination half-life was much 239 
shorter for the theoretical LLOQ of 0.05 ng/mL vs the theoretical calculation with a 240 
LLOQ at 0.03 ng/mL. These differences in calculated parameters could have effects on 241 
patients when treated with fentanyl, depending on the pharmacodynamics of the drug. 242 
While there is a relative paucity of the effects of fentanyl in cattle, adverse effects from 243 
overdosing have been reported in multiple species. 244 
Volume of distribution at steady state (27.5 L/kg) was also greater than reported values 245 
of other ruminant species such as 8.9 L/kg (sheep), 1.5 L/kg (goats), and 1.5 L/kg 246 
(alpacas)(Lovasz, Aarnes et al., 2017). The estimated systemic clearance (2.1 L/kg/hr) 247 
was consistent with other reported clearances in similar large animal species of sheep 248 
(3.6 L/kg/hr), goats (2.1 L/kg/hr), and alpacas (1.1 L/kg/hr)(Lovasz, Aarnes et al., 2017).  249 
Extraction data does not appear to be well described for fentanyl in large animal 250 
species. The total extraction of the body, reported in this study as Ebody, can be 251 
described as a percentage or ratio of the drug eliminated through one pass of the 252 
different organs contributing to clearance(Toutain & Bousquet-Melou, 2004). The 253 
extraction ratio reported for the calves in this study (0.41 ± 0.10) would be consistent 254 
with an extraction percentage of 41.0 ± 10%. This appears to be greater than what has 255 
been described in neonatal lambs, as a fentanyl extraction percentage of 16.5 ± 3.0% 256 
has been reported(Kuhls, Gauntlett et al., 1995). As reported by Toutain et al[11], an 257 
extraction value of 0.3 (30%) or higher is indicative of high a clearance of fentanyl in 258 
calves.  259 
In adult humans fentanyl is mainly metabolized by cytochrome P450 3A enzymes to 260 
norfentanyl(Clavijo, Thomas et al., 2011). Two other minor metabolites, desproprionyl 261 
fentanyl, and hydroxyfentanyl are accomplished by amide hydrolysis and alkyl 262 
hydroxylation respectively(Clavijo, Thomas et al., 2011). The pharmacokinetics of 263 
norfentanyl are not widely described in veterinary species, with one recent report 264 
identifying parameters in chickens administered fentanyl via a transdermal patch 265 
system.  266 
Page 13 of 25
Journal of Veterinary Pharmacology and Therapeutics
Journal of Veterinary Pharmacology and Therapeutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 14 
Norfentanyl pharmacokinetics in this study significantly varied from that of the parent 267 
compound fentanyl. Notably, the elimination half life of norfentanyl was estimated at 268 
only 3.6 hours vs. 12.7 hours for its parent. Since a metabolite cannot be eliminated 269 
faster than it is being formed, the elimination half-life of norfentanyl can either be similar 270 
or longer than that of fentanyl, but not shorter. Therefore, the apparent ‘shorter’ half-life 271 
of norfentanyl is most likely a consequence of the bioanalytical cut-off, such that the 272 
reported half-life of 3.6 hours relate to the distribution, rather than the elimination of 273 
norfentanyl. This is supported by the similarities in the estimated half-life between 274 
fentanyl and norfentanyl as the theoretical LLOQ for the parent increased from 0.03 to 275 
0.05 ng/mL. As no norfentanyl concentrations were measured below 0.05 ng/mL, the 276 
PK parameters remain unchanged if re-evaluated with the theoretical LLOQ of 0.05 277 
ng/mL. 278 
At this time the significance of the norfentanyl pharmacokinetic parameters is unknown 279 
as a relative paucity of comparative data for this metabolite exists in the veterinary 280 
literature. Among human toxicologists it is speculated that the smaller the ratios of blood 281 
and urine norfentanyl/fentanyl, the larger the probability of acute fentanyl intake with 282 
coexistent fentanyl abstinence, which then predisposes to fentanyl toxicity(Ruan, 283 
Chiravuri et al., 2016). Further studies of norfentanyl are necessary to determine the 284 
clinical significance of this metabolite in cattle. 285 
 286 
Limitations 287 
A limitation of this study was the relatively small number of calves used. While eight 288 
animals are commonly used in PK studies, it might not account for population variability. 289 
Similarly, all of the animals were calves of the approximate same age which may not be 290 
reflective of adult cattle. Norfentanyl calculations were limited, as a metabolite, 291 
clearance and volumes of distribution cannot be calculated without a priori knowledge 292 
on the fractional conversion of fentanyl into norfentanyl. Additional pharmacokinetic 293 
studies with norfentanyl per se should consider intravenous injection of the metabolite to 294 
derive such parameters. 295 
 296 
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Conclusions 297 
In conclusion, fentanyl citrate administered intravenously reaches systemic peak 298 
concentrations associated with analgesia in other veterinary species. Further work 299 
needs to be completed to investigate the analgesic properties of fentanyl in calves. In 300 
addition, more work into alternative dosing formulations, such as continuous rate 301 
infusion and transdermal patches needs to be done to evaluate the suitability of these 302 
routes for bovine practice. Finally, interpretation of pharmacokinetics warrants close 303 
investigation of the quantification limits used, as increased or decreased limits of 304 
quantification can significantly alter the estimation of pharmacokinetic parameters, 305 
which could have important implications for dosing regimen selection in clinical practice. 306 
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Table 1. Pharmacokinetic parameters for fentanyl and norfentanyl in study calves.  1 
Compound Parameter Unit Geomean Median Min Max 
 C0 ng/mL 1.5 1.6 1.0 2.0 
 AUClast ng/mL*hr 2.0 2.1 1.6 2.3 
F
e
n
t
a
n
y
l
 
AUCinf ng/mL*hr 2.5 2.3 1.8 3.3 
%AUCextr % 15.4 11.0 7.0 48.1 
AUMCinf ng/mL*hr
2  31.1 17.1 16.2 131.1 
MRT hr 12.4 8.8 7.3 39.3 
CL mL/hr/kg 1999 2167 1505 2821 
T1/2 (λz) hr 12.7 9.1 7.5 35.1 
Vss L/kg 24.8 23.3 15.8 58.8 
Varea L/kg 36.7 34.0 23.4 76.1 
 Cmax ng/mL 0.3 0.3 0.2 0.5 
 Tmax hr 1.1 1.5 0.08 2.5 
N
o
r
f
e
n
t
a
n
y
l
 
AUCinf ng/mL*hr 1.8 2.2 0.9 2.9 
%AUCextr % 7.2 7.2 3.6 13.1 
AUMCinf ng/mL*hr
2  10.6 13.4 4.6 16.5 
MRT hr 5.9 6.0 4.8 7.9 
T1/2 (λz) hr 3.6 3.2 2.9 5.4 
 2 
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The following parameters were calculated for IV administration: C0, plasma concentration back extrapolated to time 0 3 
using log-linear regression of the ﬁrst two time points; Cmax, maximum concentration; Tmax, time of maximum 4 
concentration; AUCinf, area under the curve extrapolated to inﬁnity, using the linear trapezoidal method; %AUCextrap, 5 
percent of the AUC extrapolated to inﬁnity; CL, plasma clearance; T½ ƛz, terminal half-life; ƛz, terminal rate constant; MRT, 6 
mean residence time; Vss, Volume of distribution at steady state; Varea, volume of distribution during the elimination phase. 7 
 8 
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Table 2. Average (± S.D) fentanyl pharmacokinetic parameters with the study lower limit 1 
of quantification (LLOQ) of 0.03 ng/mL compared to a theoretical LLOQ of 0.05 ng/mL. 2 
See Table 1 for definition of abbreviated terms. 3 
 4 
Parameter Unit Calves (Current) Calves (Hypothetical) 
LLOQ ng/mL 0.03 0.05 
AUCinf ng/mL*hr 2.6 ± 0.6 1.5 ± 0.3 
CL mL/hr/kg 2061 ± 491 3371 ± 813 
T1/2 (λz) hr 14.9 ± 9.9 3.0 ± 0.9 
λz 1/hr 0.06 ± 0.03 0.30 ± 0.1 
MRT hr 15.3 ± 11.6 2.7 ± 0.6 
Vss L/kg 27.5 ± 14.7 8.8 ± 1.2 
Varea L/kg 39.6 ± 17.1 13.9 ± 3.0 
  5 
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Table 3. Pharmacokinetic parameters of fentanyl in other large animal species. See Table 1 for definition of abbreviated 1 
terms. 2 
 3 
Parameter Unit Calves 
(Actual) 
Calves 
(Hypothetical) 
Goats 
(Carroll, 1999) 
Sheep 
(Ahern, 2010) 
Alpacas 
(Lovasz, 2016) 
LLOQ ng/mL 0.03 0.05 0.10 0.01 0.05 
Dose µg/kg 5.0 5.0 2.5 2.5 2 
T1/2 (λz) hr 14.9 3.0 1.2 3.1 1.2 
MRT  hr 15.3 2.7 0.80 - 1.3 
 4 
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Figure 1: Individual fentanyl pharmacokinetic time-course (log10, mean ± 1 S.D) 1 
following intravenous bolus dosing at 5.0 µg/kg.  2 
 3 
An initial fentanyl concentration of 1.5 ng/mL was observed. As evident by the standard 4 
deviation bars very little individual to individual variation was noted. The dashed line 5 
represents the lower limit of quantification for the assay (0.03 ng/mL). 6 
 7 
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Figure 2: Individual norfentanyl pharmacokinetic time-course (log10, mean ± 1 S.D) 1 
following intravenous bolus dosing of fentanyl at 5.0 µg/kg. 2 
N
o
rf
e
n
ta
n
y
l 
(n
g
/m
L
)
 3 
A maximum norfentanyl concentration of 0.3 ng/mL was observed, with a time to 4 
maximum concentration of 1.1 hours. As evidenced by the standard deviation bars more 5 
individual to individual variation was noted as opposed to fentanyl. After 600 minutes all 6 
values were below the LLOQ of 0.03 ng/ml (LLOQ represented as dashed line). 7 
 8 
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